文献速递肝病

从NAFLD到MAFLD:术语过早变更的影响

From NAFLD to MAFLD: Implications of a Premature Change in Terminology.
PubMed 文献 · Hepatology · 2021-02-06

本文讨论将非酒精性脂肪性肝病(NAFLD)更名为代谢相关脂肪性肝病(MAFLD)的提议。作者认为MAFLD虽反映代谢风险因素但仍不理想,在缺乏对疾病分子基础新理解、风险分层新见解的情况下更名会造成不必要的混乱,建议成立真正的国际共识小组评估更名的影响。

要点

  • 作者认为MAFLD这一名称仍不理想,留有大量歧义。
  • 在缺乏对疾病分子基础新理解的情况下更名可造成不必要的混乱。
  • 作者建议成立包含AASLD、EASL、ALEH、APASL等的国际共识小组评估更名。

核心结论

  • 作者警示:在不理解广泛影响的情况下更改术语可能对该领域产生负面影响,建议成立真正的国际共识小组评估更名的依据与后果。

研究设计与样本

  • 本文为关于NAFLD更名为MAFLD的术语讨论文章,未报告系统检索范围或样本量。

主要发现

  • MAFLD反映了该肝病的相关风险因素,但该术语仍不理想,留有大量歧义。
  • 在缺乏对疾病实体分子基础的新理解、风险分层的新见解或其他重要方面新认识的情况下更改术语,可造成不必要的混乱并可能对该领域产生负面影响。
  • 在该领域面临疾病认知及药物研发和生物标志物发现可接受终点 clarity 等重大挑战之际,在不全面评估的情况下从一个不理想名称改为另一个不理想名称,预计会加深这些挑战。
  • 作者建议成立真正的国际共识小组,纳入所有相关科学肝脏学会(AASLD、EASL、ALEH、APASL)、患者倡导组织、生物制药行业、监管机构和政策制定者;共识会议必须基于现有证据评估更改术语的影响和后果并提出推动该领域前进的建议。

临床怎么用

  • 作者建议成立真正的国际共识小组(纳入AASLD、EASL、ALEH、APASL、患者倡导组织、生物制药行业、监管机构和政策制定者)评估更名的影响和后果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the substantial gains in our understanding of NAFLD/NASH over the past 2 decades, there has been some dissatisfaction with the terminology "non-alcoholic" which overemphasizes "alcohol" and underemphasizes the root cause of this liver disease, namely, the predisposing metabolic risk factors. As a potential remedy, a name change from NAFLD to metabolic associated fatty liver disease (MAFLD) has been proposed. Although MAFLD reflects the relevant risk factors for this liver disease, this term is still suboptimal, leaving a great deal of ambiguity. Here, we caution that changing the name without understanding its broad implications can have a negative impact on the field. In this context, changing the terminology without new understanding of the molecular basis of the disease entity, new insights in risk stratification or other important aspect of this liver disease, can create unnecessary confusion which could negatively impact the field. At a time when the field is facing substantial challenges around disease awareness as well as clarity of acceptable endpoints for drug development and biomarker discovery, changing the terminology from one suboptimal name to another suboptimal name without full assessment is expected to deepen these challenges. In the context of this debate about terminology, we recommend the creation of a true international consensus group to include all the relevant scientific liver societies (AASLD, EASL, ALEH, APASL), patient advocacy organizations, bio-pharmaceutical industry, regulatory agencies and policy makers. A consensus meeting must assess the impact and consequences of changing the terminology based on the available evidence and make recommendations that will move the field forward. By this approach, a true collaborative international and inclusive consensus can be adopted by all stakeholders dealing with this important global liver disease.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: Implications of a Premature Change in Terminology. Hepatology. 2021. PMID: 32544255. doi:10.1002/hep.31420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。